Opening the Room: Who's in it with us?

• Who from your organization will be participating in evaluating this analytics platform? Please list names, titles, and their expected involvement.
• Which of these stakeholder groups will have decision influence on this engagement? Options: ACO Medical Director, CFO / Finance, CMO / Clinical Leadership, VP/Director Population Health, Chief Data Officer / IT, Chief Operating Officer, Care Management Leadership, Physician Council / Clinic Leads, Board / Executive Committee, Other
• Who will be the primary day-to-day point of contact and who will serve as the executive sponsor for this initiative?
• Which single stakeholder currently feels the most urgency to move forward with better analytics and why? Options: ACO Medical Director, CFO, VP Population Health, Clinical Operations Lead, Physician Leadership, Other
• How does your team usually make decisions for initiatives like this—consensus, executive-led, procurement-driven, or committee vote? Options: Consensus across stakeholders, Executive sponsor decision, Procurement/Legal-led process, Formal committee vote, Other

Who's Really Holding the Keys?

• If the contract landed on a desk tomorrow, who would actually have authority to sign and why would they approve it? Options: CFO / Finance, Executive Sponsor (CEO/COO), Board or Executive Committee, Procurement / Legal, Clinical Governance (CMO/Medical Board), Other
• Walk us through a recent vendor selection—who championed it, who opposed it, and what made the difference?
• Which formal approval steps are required for commercial engagement in your organization? Options: Legal review, Procurement approval, IT/security signoff, Finance/CFO signoff, Clinical governance/medical board, Data governance, Board approval, Other
• Do you operate inside procurement windows, annual budget cycles, or other timing constraints that will affect contract timing? Options: Quarterly budget review, Annual budget cycle, Procurement windows only, Ad-hoc approvals, No specific constraints, Unsure
• Who in your organization is most likely to veto this project and what are the top concerns that would trigger a veto?

If We Miss the Mark, Who Notices?

• Whose performance metrics or incentives are most exposed if this initiative underperforms? Options: ACO Medical Director, CFO, VP Population Health, Clinical Operations Lead, Physician Leaders, Quality/Compliance Lead, Other
• How are outcomes for value-based programs currently tracked—formal reviews, incentive cliffs, or informal check-ins? Options: Formal monthly performance reviews, Quarterly executive reviews, Annual incentives tied to shared savings, Ad-hoc/informal updates, No formal tracking
• Describe a past analytics or vendor effort that failed to meet expectations—what broke down and how did that impact stakeholders?
• When leaders lose faith in analytics outputs, which criticisms surface most often? Options: Data is too late, Metrics aren’t actionable, Provider-level detail is missing, Attribution is disputed, Tool is not user-friendly, Other
• If early deployment shows warning signs, how would you prefer we escalate and communicate those issues? Options: Immediate call with exec sponsor, Weekly written status reports, Executive dashboard alerts, Weekly sync with project team, Other

What Would 'Good' Actually Look Like for Each Team?

• If clinical leadership had to sign off today, what measurable changes would make them declare this a success?
• From a finance perspective, what exact financial targets or tolerances (e.g., PMPM, shared savings %) would justify continued investment?
• Which operational outcomes are highest priority for your operations leaders? Options: Reduction in avoidable ED visits, Reduced readmissions, Faster claims reconciliation, Improved care transitions, Lower administrative burden on providers, Other
• How do provider-facing stakeholders define ‘actionable’—what timeliness and granularity do they need to engage clinicians? Options: Patient-level within 30–90 days, Monthly provider-level drilldown, Condition/episode-specific reports, Near-real-time alerts, Other
• Select the success signals that would most influence your decision to scale this solution. Options: Total cost of care reduction, Improved quality scores (HEDIS/other), Provider adoption rate, Attribution accuracy, Timeliness of data, Reduction in avoidable utilization, Other

Unseen Friction: Politics, Trust, and Data Skepticism

• Where do trust gaps live today—between clinicians and finance, clinicians and analytics, or within the executive team? Options: Clinicians vs Finance, Clinicians vs Analytics, Analytics vs Executive Team, IT vs Clinical, Other
• Describe a time when analytics data provoked strong pushback—what emotions surfaced and how was it handled?
• How open are physician leaders to being shown provider-level performance in scorecards? Options: Very open, Somewhat open, Reluctant, Strongly opposed, Depends on anonymity/aggregation
• Which change-management resources are available to support provider adoption here? Options: Clinical champions, Dedicated training team, Change management lead, Internal communications team, No formal resources, Other
• If we proposed co-validation of attribution and metrics with your clinicians, what concerns would still keep you cautious?

Timeline Reality Check: When Does This Matter?

• If you had to place a non-negotiable deadline on seeing initial impact, when is it and why? Options: 30 days, 60 days, 90 days, 6 months, By next contract renewal, Other
• What external calendar events (contract renewals, reporting deadlines, board meetings) create hard milestones for this project? Options: Contract renewal, Medicare/MA reporting deadlines, Quarterly board review, Budget cycle, Regulatory audit window, Other
• Given common claims latency (e.g., 60–90 days), how do you currently manage expectations for early results?
• How flexible is your internal timeline if integration or validation requires more time than expected? Options: Very flexible, Somewhat flexible, Rigid / fixed deadline, Unsure
• What concrete milestones and checkpoints would you expect during the first 90 days?

The Budget & Risk Trade-offs You’re Willing to Make

• What's the maximum financial or operational risk your organization is willing to absorb for a vendor to deliver meaningful change?
• Which commercial model aligns best with your organization's risk appetite? Options: Fixed subscription, Success-based / shared savings, Hybrid (base + success), Pilot/POC with limited spend, Other
• How much runway—budget and executive patience—is typically given to pilots before a go/no-go decision? Options: 1–3 months, 3–6 months, 6–12 months, Depends on pilot scope, Unsure
• Which contractual protections are must-haves for you (select all that apply)? Options: SLA with financial penalties, Data ownership and return rights, Termination for convenience, Acceptance criteria tied to payment, Indemnity/insurance clauses, Other
• If a success fee is considered, which financial metrics would you be comfortable tying payment to? Options: Total cost of care reduction (PMPM), Shared savings %, Avoidable admissions avoided, Improvement in specific quality measures, Reduced utilization per 1,000, Other

How Will We Validate and Celebrate Early Wins?

• What would an early win look like that no one could argue with—an indisputable, measurable result?
• Which existing data sources and reports do you trust most today to prove impact? Options: Claims extracts, Financial P&L / cost reports, Provider scorecards, EMR / clinical reports, Quality/HEDIS dashboards, Other
• Who must sign acceptance that early milestones were achieved? Options: Executive sponsor, Clinical lead / Medical Director, Finance lead / CFO, Cross-functional steering committee, Other
• How should early results be communicated to your physician network to maximize credibility and adoption? Options: Provider-level dashboards, Weekly summary emails, Town-hall presentations, One-on-one provider reviews, Integrated EHR notifications, Other
• What measurement cadence builds confidence—weekly, monthly, quarterly—and why? Options: Weekly, Bi-weekly, Monthly, Quarterly, Other

Mapping Responsibilities: Who Owns What

• Where do handoffs tend to break down today—between clinical, finance, operations, IT, or vendor teams? Options: Clinical leadership, Finance/CFO, Operations, IT/Data engineering, Care management, Vendor handoffs, Other
• List the internal teams that must be involved in implementation and the primary responsibility you expect each to own.
• Which of these responsibilities would you expect our team to take on as vendor-delivered services? Options: Data ingestion & mapping, Attribution reconciliation, Dashboard configuration & UX, Provider and admin training, Ongoing analytics & monitoring, Governance facilitation, Other
• What SLA or response expectations should we plan for between our implementation team and yours? Options: 24–48 hour response, 3–5 business days, Weekly touchpoints, Monthly steering committee, Other
• After deployment, who will own ongoing governance and performance review? Options: Clinical governance committee, Finance operations owner, Cross-functional steering committee, Vendor-managed governance, Other

Commitment & Next Steps: What Would Make You Say Yes?

• If you could pin one non-negotiable condition that would make you comfortable signing, what would it be?
• What outstanding questions or proof points must be resolved before you would recommend this to leadership?
• Which next step from us would be most helpful right now? Options: Technical deep-dive with IT/security, Pilot using retrospective claims data, Executive-level commercial review, Clinical co-validation workshop, Legal/contract template review, Other
• How soon should we schedule a follow-up to align on scope, timeline, and responsibilities? Options: This week, Within 2 weeks, In a month, After internal approvals, Other
• Who else from your organization should be included in that follow-up meeting (names and roles)?

Start Here: Tell Us Who You’re Bringing to the Table

• What is your primary role and how you are involved in value-based contracts? Options: ACO Medical Director, VP/Director Population Health, Health System CFO, CMO/Clinical Leader, Analytics Director, Other
• Which payer types make up the majority of your attributed population today? Options: Medicare Shared Savings (ACO), Medicare Advantage, Commercial risk, Medicaid managed care, Mixed
• Approximately how many attributed lives or unique members are in scope for your value-based contracts? Options: <10k, 10k–50k, 50k–150k, 150k–500k, >500k
• Who are the key decision-makers we should align with during discovery (roles and names if available)?
• What's the primary outcome your leadership cares about this year (choose one)? Options: Lower total cost of care, Improve quality metrics/compliance, Increase provider adoption of pathways, Maximize shared savings, Reduce avoidable utilization

If Your Data Could Talk, It Would Tell Us Where It Hurts

• How confident are you in the accuracy of your claims-derived cost and utilization metrics today? Options: Very confident, Somewhat confident, Neutral, Skeptical, Not confident at all
• Which data sources do you currently combine to measure total cost of care and quality? (select all that apply) Options: Commercial claims paid, Medicare FFS claims, Medicare Advantage encounter data, Medicaid claims/encounters, EHR clinical data, Pharmacy claims, Cost/accounting ledgers, Other
• How do you currently ingest claims data into analytics (choose all that apply)? Options: Direct payer feeds (API/SFTP), Clearinghouse exports, Vendor-supplied normalized files, Manual batch uploads, We don’t have a formal ingestion process
• What is your typical end-to-end claims latency (from service date to usable claim in your analytics)? Options: <30 days, 30–60 days, 60–90 days, 90–180 days, >180 days, Varies widely by payer
• Which parts of the claims pipeline cause the most frustration (mapping, late adjudication, denials, remits, other)? Options: Mapping/normalization, Late adjudication/payments, Denied/aged claims, Pharmacy lag, Missing provider identifiers, Other
• Tell us about a recent example where delayed or missing claims directly impacted a clinical or financial decision.
• Who owns ETL/data quality internally and what checks are currently run before metrics are published? Options: In-house data engineering, Population health analytics team, Finance/actuarial, Third-party vendor, No single owner

Who Really Owns Attribution — and Does Everyone Agree?

• If attribution were a courtroom, how contested would the verdict be across your stakeholders? Options: Rarely contested, Occasionally disputed, Frequently disputed, Continuously contested
• What attribution method(s) are you currently using or required by contract (select all that apply)? Options: Prospective assignment, Retrospective claims-based, Panel-based attribution, Majority of visits, Custom contractual definition, Payer-specified algorithm
• How often do you reconcile attribution between clinical rosters and payer lists, and who signs off? Options: Daily/real-time, Weekly, Monthly, Quarterly, Infrequently or ad-hoc
• What are the top reasons providers dispute attribution, and how long do disputes typically take to resolve? Options: Missing visits in claims, Incorrect TIN/NPI mapping, Delay in encounter submission, Roster mismatches, Payer coding differences
• Describe a recent attribution disagreement: who raised it, the root cause, and the outcome.
• What level of attribution transparency is required for provider-level performance conversations (claims-line detail, visit-level evidence, aggregated summaries)? Options: Claims-line detail, Visit-level summaries, Aggregated monthly metrics, Contract-level summaries only

When Reports Arrive, Do They Move People to Action?

• Is the information you share with physician leaders viewed as timely and actionable or as 'nice to know'? Options: Timely and actionable, Somewhat actionable, Informative but not actionable, Ignored
• What reporting cadence currently drives decisions across clinical, financial, and operational teams? Options: Real-time dashboards, Weekly, Monthly, Quarterly, Event-triggered only
• How are reports consumed by clinicians and leaders (EHR inbox, email PDFs, BI portal, meetings, other)? Options: EHR inbox/alerts, Email reports/PDFs, BI/dashboard portal, Regular leadership meetings, Ad hoc data requests
• What level of provider-level drilldown do you need to make a coaching conversation credible (panel-level, NPI-level, visit, claim-line)? Options: Panel-level summary, NPI/provider level, Visit-level with notes, Claim-line detail
• Give an example of a time a report led to a measurable change in care or cost—what enabled that shift?
• Which audiences typically don’t act on the reports you publish, and why do you think that is? Options: Primary care physicians, Specialists, Practice managers, Finance, Care managers, Other

What Makes Physicians Tune Out (Even When the Numbers Look Bad)?

• Why do clinicians push back on analytic findings—what do they say is missing or misleading? Options: Data is out of date, Not clinically granular, Attribution seems wrong, Metrics feel punitive, Lack of workflow integration, Other
• How often do clinicians request case-level evidence before changing practice, and what form of evidence convinces them? Options: Always, Often, Sometimes, Rarely, Never
• What engagement tactics have you tried (peer comparisons, outreach scripts, financial incentives, CME sessions) and what worked or failed? Options: Peer benchmarking, One-to-one coaching, Financial incentives, Group education/CME, Embedded EHR alerts, None tried
• Describe an instance where a physician changed behavior based on analytics—what was different about that interaction?
• Which clinician-facing formats get the best response: single metric scorecards, case lists, narrative patient stories, or real-time alerts? Options: Single metric scorecards, Case lists for outreach, Narrative patient stories, Real-time EHR alerts, Interactive dashboards

Imagine You Could Prove Savings Next Quarter — What Would That Require?

• If leadership asked for a credible, provider-level savings estimate in 90 days, how achievable is that with current data and processes? Options: Very achievable, Achievable with effort, Possible but unlikely, Not achievable
• Which outcome signals would make stakeholders accept a savings claim (cost per member, readmission reduction, utilization drops, quality improvement)? Options: Total cost per member, ED visit reduction, Inpatient days reduced, Readmissions, Quality measure improvements, Other
• What level of statistical or actuarial validation does finance require before accepting a savings estimate? Options: Formal actuarial sign-off, Peer-reviewed methodology, Internal finance review, Basic reconciliations only
• Who must sign off on acceptance criteria for success (names/roles), and what acceptance hurdles have sunk prior pilots?
• What timeframe do you think is realistic to demonstrate provider-level adoption changes that lead to savings? Options: 30–60 days, 60–90 days, 3–6 months, 6–12 months

Integration Reality Check: Can We Actually Connect?

• Which technical connection types are available for claims and clinical feeds at your organization? Options: Secure API, SFTP batch files, HL7/FHIR, Vendor-hosted normalized exports, Manual CSV uploads, No current connectors
• What security and compliance controls must be in place before any data exchange (BAA, encryption, IP allowlist, penetration testing)? Options: Business Associate Agreement (BAA), AES/TLS encryption, IP allowlisting, Vulnerability/pen testing, SOC2/ISO attestation, Other
• How many test environments and months of retrospective data will you make available for validation? Options: 1–3 months, 3–6 months, 6–12 months, 12+ months, Only production
• Who are the operational owners for integrations (IT, data engineering, vendor management, security) and what SLA expectations do they set? Options: IT/Infrastructure, Data engineering/BI, Vendor management, Security/compliance, Population health ops
• Describe any past integration blockers (firewall rules, payer approvals, data schema mismatches) and how long they took to resolve.

Risks, Assumptions, and the Things People Don’t Say Out Loud

• What assumptions are we making about your data, people, or processes that, if wrong, would sink the project?
• Which risks keep you awake regarding analytics-driven initiatives (budget, governance, provider backlash, regulatory scrutiny)? Options: Budget constraints, Governance misalignment, Provider resistance, Regulatory/compliance risk, Data quality/latency, Other
• How much contingency budget/time do you have to handle unexpected ETL or attribution work? Options: None, < 10% of project, 10–20% buffer, >20% buffer
• If we surfaced a major attribution or claims gap in month one, what decision process would you follow to pause, fix, or continue?
• Who are the informal influencers (clinical champions or skeptics) we should engage early to de-risk rollout?

Closing the Loop: What Would Make This an Easy Yes?

• What are the top three criteria leadership will use to decide whether to proceed with a partnership like ours?
• What timeline do you have in mind for a pilot or initial deployment? Options: Immediate (30 days), Short (60–90 days), Medium (3–6 months), Longer (6–12 months)
• Which stakeholders need to be engaged and on what cadence to reach a decision (weekly syncs, steering committee, exec review)? Options: Weekly working team, Biweekly steering committee, Monthly exec review, Ad hoc
• What would be a minimally viable first milestone that would convince you we’re on the right track (e.g., validated attribution for a subset, reconciled cost per member, provider-level case list)? Options: Validated attribution for subset, Reconciled cost per member, Provider-level case list, Pilot ROI projection
• What final question or concern would you want addressed before greenlighting a pilot?

Setting the Stage: Who’s accountable and what feels like a win?

• Which single role will be most accountable for the program meeting its first-year targets? Options: ACO Medical Director, VP/Director Population Health, Health System CFO, Chief Quality Officer, Director of Clinical Analytics, Other
• When you say “success” for this engagement over the first 12 months, pick the top 2 outcomes you’d point to in a board meeting. Options: Total cost of care reduction (%), Improved quality scores (e.g., HEDIS/HCC), Provider adoption/engagement rate, Avoided penalties / retained shared savings, Faster data-to-insight cycle, Operational workflow changes implemented
• Tell us about one recent win or small success your team had with analytics — what changed and who noticed?
• On a scale, how confident are you today that your organization can act on provider-level insights within 60 days of seeing them? Options: Very confident, Somewhat confident, Neutral, Not confident, No idea
• Who else needs to be in the room for decisions about data, clinical change, and finance to actually move forward? Options: Physician leaders/chiefs, IT/data engineering, Contracting/legal, Care management leadership, Finance/CFO office, Operational leadership (clinic/hospital), Other

If the data could lie to you, what would it say? (Where it breaks)

• What if your claims data is giving a comforting but inaccurate story—where would that mislead you most?
• Which claim feeds do you currently receive (select all that apply) and which arrive with the longest delay? Options: Institutional inpatient claims, Institutional outpatient claims, Professional/physician claims, Pharmacy claims, Capitation / PMPM, Dental/auxiliary
• How long is the typical latency from service date to receiving usable claims for each source (give examples if variable)? Options: <30 days, 31–60 days, 61–90 days, 91–180 days, >180 days, Varies significantly by payer
• Describe a concrete example where delayed or partial claims data led to a missed clinical or financial opportunity.
• Which data elements do you trust least when making provider-level decisions (e.g., attribution, facility identifiers, place of service, primary diagnosis)? Options: Attribution, Facility identifiers, Provider NPI mapping, Place of service, Diagnosis coding consistency, Cost/allowed amount fields

Who pulls the trigger? Power, politics, and the real decision map

• If the person who owns clinical decisions doesn’t trust the data, what tends to happen—do you pause, pilot, or change course? Options: Pause until validated, Run a small pilot, Proceed with caveats, Escalate governance, Other
• List the exact stakeholders (name/role) who must sign off on: data model, attribution, and commercial terms.
• How do competing incentives show up between clinical leaders and finance — give one recent example where tension slowed action.
• What governance cadence have you relied on historically for rapid decisions (weekly, biweekly, monthly)? Which cadence actually resulted in decisions? Options: Weekly, Biweekly, Monthly, Quarterly, Ad-hoc
• Who would be your internal champion for getting physicians to trust a new analytics workflow? Options: ACO Medical Director, Chief of Primary Care, Clinical informatics lead, Physician champion(s), Nurse/care manager leader, No clear champion yet

Attribution: The rules that change incentives — are we really aligned?

• If your attribution rules shifted tomorrow, would your shared-savings payouts or provider rankings materially change? Options: Yes, significantly, Yes, somewhat, No, minimally, Unsure
• Which attribution model(s) are you currently using or required by payers (select all that apply)? Options: 30-day plurality, 90-day plurality, Episode-based attribution, Prospective attribution roster, Medicare ACO assignment, Custom/Proprietary model
• How often do providers dispute attribution or membership, and what’s your current dispute resolution process? Options: Weekly, Monthly, Quarterly, Rarely/never, No formal process
• Share a recent attribution dispute example and what resolved it — or why it remains unresolved.
• What level of provider-level transparency (visit-level, claim-level, episode-level) do physician leaders need to act confidently? Options: Visit-level / claim-level detail, Episode summaries with drilldown, Provider scorecards only, Aggregated trends

Why aren’t physicians opening the dashboard? Turning data into a conversation they’ll join

• Why do you think physician leaders have resisted previous analytics efforts—what feeling or belief holds them back?
• What formats have you found most effective to engage physicians (select top 2)? Options: Email summaries, One-page provider scorecards, Case-based lists with drilldowns, Short in-person huddles, EHR-integrated alerts, Monthly performance meetings
• How much time per month can a typical physician realistically allocate to reviewing performance details? Options: <30 minutes, 30–60 minutes, 1–2 hours, >2 hours
• Who on your team has successfully persuaded skeptical physicians before, and what approach did they use?
• What would make a physician say, “This is worth my time” — be specific (e.g., patient stories, dollars at stake, simple action steps)?

If the numbers were off, how wrong can they be before people stop trusting them?

• Imagine we’re five weeks post-go-live and something looks off—what error threshold would trigger a rollback or formal pause? Options: >1% variance, >5% variance, >10% variance, Decision based on stakeholder judgment, No predefined threshold
• Which metrics must reconcile perfectly to your satisfaction (select all critical ones)? Options: Total cost of care, Utilization by setting (inpatient/ED), Quality measures (HEDIS/ACO), Provider-level cost, Risk score/HCC capture, Member attribution
• What sample test cases or named providers would you want us to validate before broader rollout?
• Describe your current acceptance sign-off flow — who signs off and what evidence do they require?
• What tolerance for changes in early months would you accept as we refine models and feeds? Options: Tight tolerance — minimal changes, Moderate — expect iterative tweaks, Flexible — still in discovery, Unsure

Integration Reality Check: Are the pipes actually ready?

• Is your technical team confident they can provide the necessary data extracts and test feeds within the timeline you expect? Options: Yes — confident, Somewhat — with caveats, No — likely delays, Unsure
• Which of these access methods can you provide for initial integration (select all that apply)? Options: SFTP file drops, API endpoints, Direct DB access, HL7 interfaces, Flat-file via secure upload, No standard method yet
• List any security, compliance, or contracting steps that historically add time to integrations (e.g., BAAs, PO approvals).
• Do you maintain a single canonical provider roster, and how often is it refreshed? Options: Yes — daily, Yes — weekly, Yes — monthly, Multiple rosters/no canonical, No formal roster
• What non-technical risks worry you most about integration (e.g., staffing turnover, competing projects, vendor fatigue)?

Timing, sequencing, and the price of delays — who bears the risk?

• If implementation slips three months, which impact concerns you most? Options: Lost savings opportunity, Provider trust erosion, Budget/cost overruns, Regulatory/contractual risk, Team bandwidth strain
• What is your ideal go-live month/quarter, and what immovable deadlines drive that target (e.g., contract year, reporting deadlines)?
• Which activities must happen before go-live for you to feel comfortable (select top 3)? Options: Data reconciliations complete, Provider training delivered, Governance cadence established, Acceptance sign-off from stakeholders, Provider roster validated
• Are you open to a phased go-live (pilot group first) and what would make a pilot successful in your view? Options: Yes — pilot preferred, Yes — but only limited scenarios, No — prefer full rollout, Unsure
• What internal dependencies present the greatest scheduling risk (e.g., IT freeze, fiscal year close)?

Contracts & Commitments: What needs to be written down?

• What commercial terms or SLAs would make you feel protected enough to move forward today? Options: Data latency guarantees, Attribution dispute resolution, Performance benchmarks, Dedicated support resources, Termination/exit terms
• Which acceptance criteria are non-negotiable for final payment/milestone sign-off? Options: Reconciled cost metrics, Provider-level drilldown capability, End-user training completion, Successful test feed transfer, Governance cadence established
• Have you used holdbacks, milestone payments, or penalties in prior vendor contracts—what worked and what didn’t?
• If we propose a remediation SLA (e.g., fix critical data errors within X days), what timeframe would be meaningful to you? Options: 24–48 hours, 3–5 business days, 1–2 weeks, Longer/depends on issue
• Who on your legal/contracting team should be involved in drafting these terms, and by when would you need a draft to review?

Psychological Readiness: Are you, your leaders, and your clinicians ready to change?

• If nothing changes in the next 90 days, what outcome would you personally regret most?
• How open is leadership to iterative learning versus wanting everything proven before any change (pick one)? Options: Iterative learning/adaptive, Prefer fully proven before change, Hybrid — depends on area, Unsure
• What small, low-risk first step would signal momentum to your team and clinicians? Options: Pilot with 5–10 providers, One focused metric validated, Monthly provider huddle, Targeted training session
• Who should be our internal points of contact for day-to-day decisions and who for escalation (name/role)?
• Realistically, when could your organization commit resources to start integration activities (select one)? Options: Immediately, In 2–4 weeks, In 1–3 months, More than 3 months, Unsure

A Quick Snapshot: Who You Are and What You're Trying to Save

• What's your role and which hat do you wear most often in value-based contracts? Options: ACO Medical Director, VP/Director Population Health, CFO/Finance Lead, Chief Quality Officer, IT/Data Lead, Other
• Which risk arrangements are you actively managing right now? Options: MSSP/ACO, Medicare Advantage, Commercial downside risk, Medicaid managed care, Hybrid/Other
• What are the top 3 outcomes leadership expects from analytics this year (e.g., % savings, quality targets, provider adoption)?
• What deadline or reporting milestone is creating the most pressure to show results? Options: Quarter-end, Contract renewal, SSP reconciliation, Board/Executive review, No fixed deadline
• Roughly how many attributed lives does the organization manage under value risk? Options: <10k, 10k–50k, 50k–150k, 150k–500k, >500k

Are We Comfortable With the Story Your Data Tells?

• If someone asked you whether your cost and quality metrics are 'trusted' by clinicians and finance, would you say yes or no—and why? Options: Yes — generally trusted, Partially trusted, No — significant trust issues
• Where have you seen the largest mismatch between the analytics narrative and what frontline clinicians believe?
• How long after care is delivered do you typically receive reconciled claims that you consider reliable for performance measurement? Options: <30 days, 30–60 days, 60–90 days, 90–180 days, >180 days
• Which of these data weaknesses cause you the most sleepless nights? Options: Missing claims, Delayed adjudication, Poor cost visibility, Incomplete clinical data, Roster errors, Attribution disagreements
• Describe a recent decision that was delayed or reversed because you couldn't trust the underlying data.

Where the Real Costs Hide (and Who’s Ignoring Them)

• What surprising cost driver has leadership consistently underestimated in your contracts?
• Which service lines or conditions concentrate the most avoidable cost today? Options: Post-acute care/SNF, Emergency utilization, High-cost procedures, Chronic disease management (e.g., CHF, COPD, DM), Behavioral health/substance use
• At the provider level today, how confident are you that attribution maps correctly to individual clinicians? Options: Very confident, Somewhat confident, Not confident, We don’t have provider-level attribution
• How often do you reconcile or audit attribution and cost at the provider or clinic level? Options: Weekly, Monthly, Quarterly, Ad hoc, Never
• Tell us about a time when a hidden cost driver changed the trajectory of a savings forecast—what happened and what did you learn?

Why Clinicians Push Back (and What Would Change Their Mind)

• Why do clinicians in your system push back on performance conversations driven by claims data? Options: Too delayed, Not actionable, Blames clinicians unfairly, Lacks clinical context, Format/UX issues
• How do you currently present performance to clinicians (e.g., dashboards, case reviews, one-on-one scorecards)? Options: Interactive dashboards, Static scorecards/PDFs, Monthly huddles/case reviews, Email summaries, We don’t present regularly
• When analytics are perceived as credible, how frequently do clinicians change practice or referral patterns? Options: Often, Sometimes, Rarely, Never
• What format or evidence most convinces clinicians to act—patient-level case, peer comparisons, financial impact, or something else? Options: Patient-level case, Peer benchmarking, Projected financial impact, Clinical guidelines alignment, Combination
• Share an example where a clinician adopted a change because analytics were presented in a way they trusted—what made that instance different?

Decision Power and the Invisible Stakeholders

• Who ultimately decides whether a performance insight becomes an operational change—and who can quietly veto it? Options: Medical Director, CFO, CMO/Chief Quality Officer, Chief Population Health Officer, Network Executives, Provider Group Leads
• Which stakeholder group is most likely to prioritize short-term revenue over long-term savings? Options: Physician groups, Hospital leadership, Finance, Payer partners, Other
• How aligned are finance, clinical leadership, and operations on attribution methodology and reconciliation cadence? Options: Fully aligned, Mostly aligned with some gaps, Significant misalignment, No alignment
• Do you have a formal governance body for value-based programs (charter, cadence, decision rights)? If yes, describe its current effectiveness. Options: Yes — effective, Yes — partially effective, Yes — ineffective, No
• Who would be the day-to-day champion and who would be the executive sponsor for analytics-driven initiatives?

What Success Really Feels Like — Beyond the Dashboard

• If you had to name the single organizational outcome that would prove our work succeeded, what would it be? Options: Net shared savings, Improved quality scores, Sustained provider behavior change, Reduced total cost of care, Improved patient outcomes
• What numeric targets for savings, quality, and provider adoption would make leadership say ‘this is working’?
• Which KPIs must move together to consider the program a success (select all that apply)? Options: Total cost of care, Admissions/ED visits, Risk-adjusted quality measures, Provider-level adoption rates, Revenue/cost reconciliation
• How quickly do you expect to see the first credible signal that interventions are working? Options: 30 days, 60–90 days, 3–6 months, 6–12 months
• If targets are met, how will you operationalize and reward sustained performance (e.g., shared savings distribution, staffing changes)?

Integration Realities: Do We Have the Data & Access We Need?

• Do you currently have automated feeds for claims, EHR, cost, and pharmacy data, or are they manual/extract-based? Options: Automated API/SFTP feeds for all, Mixed automated and manual, Mostly manual extracts, No reliable feeds
• Which vendors/systems hold the data we’ll need to integrate (select all that apply)? Options: Epic, Cerner/Oracle, Meditech, Change Healthcare claims, Payer files (specific payers), Custom data warehouse, Other
• Can your team provide test feeds and a staging environment within the typical 4–8 week integration window? Options: Yes — within 4 weeks, Yes — within 8 weeks, Possible but longer, No
• What internal resource will support ETL, mapping, and ongoing data reconciliation (role and FTE estimate)?
• What security or vendor approval steps typically slow integrations the most? Options: Legal/BAA review, Security assessment, Network access approvals, Third-party vendor procurement, Other

Validation & Acceptance — How Will You Know It's Right?

• What specific acceptance criteria would trigger user acceptance sign-off for analytics and attribution (e.g., margin of error, reconciliation parity, peer review)? Options: <5% variance vs finance, <10% variance, Full parity with internal benchmarks, Clinician validation of cases, Other
• Who must sign off on UAT and final acceptance for the pilot (names/roles)?
• Which provider-level drilldowns are non-negotiable for you to act (e.g., patient list, claim-level detail, attribution rationale)? Options: Patient-level case lists, Claim-level detail and adjudication dates, Attribution logic with flags, Risk-adjusted benchmarks, Peer and region comparisons
• Would you prefer a parallel-run validation period where our analytics run alongside your existing reports before full cutover? Options: Yes — strongly prefer parallel run, Yes — open to parallel run, No — prefer direct cutover
• What evidence or artifacts from past pilots would you want to see to feel confident about moving forward? Options: Case studies, Reconciliation templates, Demo with our data, Reference calls, Technical specs

Barriers, Trade-offs, and the Real Commitment

• If acceptance uncovers material attribution gaps, are you prepared to pause incentives until alignment occurs? Options: Yes — pause and align, No — keep incentives running, Depends on size of gap
• What internal capacity (FTEs or hours/week) can you realistically commit to discovery, UAT, and clinician outreach? Options: <5 hours/week, 5–10 hours/week, 10–20 hours/week, >20 hours/week
• Which procurement or contracting steps are likely to extend timeline (select all that apply)? Options: Formal RFP, Security/Legal review, Network executive approval, Budget cycle timing, Other
• How tolerant is executive leadership of early metric discrepancies during the validation window? Options: Very tolerant (expect noise), Somewhat tolerant, Low tolerance — needs early clarity
• What would be the single biggest internal barrier to sustaining improvements after go-live?

Next Steps — What Would Make This Partnership Irresistible?

• If we fail to start this work now, what negative impact do you foresee over the next 12 months? Options: Missed shared savings, Worse quality scores, Provider disengagement, Financial penalties, No significant impact
• Which three outcomes would make you comfortable being a public reference for this program?
• What pilot scope (population size and duration) would you consider compelling to validate value quickly? Options: Small cohort <5k lives for 3 months, Medium 5–25k lives for 3–6 months, Large >25k lives for 6–12 months, Other
• Who else should be included in the next alignment meeting to accelerate decisions (role and preferred contact)?
• Preferred cadence for discovery updates and artifacts (select all that suit you)? Options: Weekly 30-minute check-in, Bi-weekly deep-dive, Monthly steering committee, As-needed email updates, Shared collaboration workspace
• Any final concerns, non-starters, or expectations we should record before we scope a pilot?